CimCure has developed an out-of-the-box way to attack tumours. Its vaccine induces an immune response directed at the tumour vasculature. Eradication of tumour blood vessels and inhibition of their growth will lead to inhibition of tumour growth. Early results were recently published in Nature Communications.
Positron Ventures led the first capital raise, a € 5m investment round in June 2022.
Location: Netherlands, North Holland, Amsterdam
Total raised: $5.36M
Investors 1
| Date | Name | Website |
| - | Positron V... | positron.v... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 08.06.2022 | Seed | $5.36M | - |
Mentions in press and media 2
| Date | Title | Description | Source |
| 30.12.2022 | Dutch-based biotech and life sciences startups that raised f... | The Netherlands is swiftly rising to the top as a hub for healthcare and life sciences innovation. M... | siliconcan... |
| 08.06.2022 | Amsterdam-based cancer vaccine biotech startup CimCure raise... | Amsterdam-based CimCure, a biotech company developing vaccine-based cancer immunotherapy, announced ... | siliconcan... |